Ethic Inc. Purchases 35,352 Shares of The Cooper Companies, Inc. $COO

Ethic Inc. grew its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 464.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,969 shares of the medical device company’s stock after buying an additional 35,352 shares during the quarter. Ethic Inc.’s holdings in Cooper Companies were worth $2,429,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Essential Partners LLC increased its holdings in shares of Cooper Companies by 23.4% during the first quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock worth $62,000 after buying an additional 166 shares in the last quarter. Basecamp Wealth Advisors LLC raised its stake in shares of Cooper Companies by 20.8% in the first quarter. Basecamp Wealth Advisors LLC now owns 1,557 shares of the medical device company’s stock valued at $111,000 after acquiring an additional 268 shares during the last quarter. Avalon Trust Co acquired a new position in shares of Cooper Companies in the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its holdings in shares of Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after acquiring an additional 375 shares in the last quarter. Finally, New Mexico Educational Retirement Board boosted its holdings in shares of Cooper Companies by 4.3% in the 2nd quarter. New Mexico Educational Retirement Board now owns 9,700 shares of the medical device company’s stock worth $696,000 after acquiring an additional 400 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Insider Activity

In other Cooper Companies news, Director Lawrence Kurzius purchased 10,000 shares of the stock in a transaction dated Monday, September 14th. The stock was bought at an average price of $53.91 per share, for a total transaction of $539,100.00. Following the transaction, the director directly owned 21,099 shares in the company, valued at $1,137,447.09. This represents a 90.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Walter M. Rosebrough, Jr. purchased 7,000 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average cost of $54.11 per share, with a total value of $378,770.00. Following the completion of the purchase, the director owned 17,000 shares of the company’s stock, valued at $919,870. The trade was a 70.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 34,701 shares of company stock valued at $1,880,039 over the last 90 days. 2.08% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on COO shares. Needham & Company LLC decreased their price target on Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, September 10th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Mizuho set a $75.00 price objective on Cooper Companies and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Barclays raised Cooper Companies to a “hold” rating in a research note on Wednesday, October 7th. Finally, JPMorgan Chase & Co. decreased their target price on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $68.60.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $62.93 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The firm has a market cap of $11.97 billion, a P/E ratio of 21.48, a P/E/G ratio of 2.50 and a beta of 0.83. The firm has a 50 day simple moving average of $58.80 and a 200 day simple moving average of $68.33. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that allows the company to buy back $3 billion in shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Cooper Companies Company Profile

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.